Related Experiment Video

Updated: Jan 15, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.2K

Dual Targeting of Tau Kinases and Autophagy by Abemaciclib Independent of CDK4/6 Inhibition

Jihui Han1, June-Hyun Jeong1,2, Dongjoon Lee2

  • 1Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|January 14, 2026
PubMed

Insights

Abemaciclib, a breast cancer drug, shows promise for Alzheimer's disease (AD) by reducing tau pathology and cognitive decline through novel mechanisms, independent of its known targets.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • Alzheimer's disease (AD) is characterized by tau pathology, but effective tau-targeting therapies are scarce.
  • Abemaciclib, a CDK4/6 inhibitor, is approved for breast cancer treatment.

Purpose of the Study:

  • To investigate the potential of abemaciclib as a therapeutic agent for Alzheimer's disease.
  • To explore the underlying mechanisms of abemaciclib's effects in AD models.

Main Methods:

  • Utilized APPNL-F/MAPT double knock-in mouse models (dKI) and AD patient-derived brain organoids.
  • Assessed cognitive function, neurodegeneration, amyloid burden, and glial activation.
  • Investigated abemaciclib's effects on tau kinases (CaMKII, GSK3β) and autophagic pathways.

Main Results:

  • Abemaciclib significantly improved cognitive deficits and reduced neurodegeneration in AD models.
  • Therapeutic effects were observed independently of changes in amyloid levels or glial activation.
  • Abemaciclib inhibited key tau kinases (CaMKII, GSK3β) and enhanced autophagic clearance of pathological tau.

Conclusions:

  • Abemaciclib demonstrates therapeutic potential for Alzheimer's disease through novel CDK4/6-independent mechanisms.
  • The drug's dual action of suppressing tau phosphorylation and promoting tau degradation offers a promising AD treatment strategy.
  • Abemaciclib represents a potential repurposed drug for tau-targeted Alzheimer's therapy with immediate translational possibilities.
Keywords:
abemaciclibalzheimer's diseasebrain organoidsdrug repurposingtau pathology

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.1K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.4K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.3K